IBRX
ImmunityBio, Inc.
NASDAQ · USHealthcareBiotechnology
$7.50-2.41%
Price as of Jul 20, 2026
IBRX financials
ImmunityBio, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $113.3M | $14.7M | $622.0K | $240.0K |
| Cost of revenue | $753.0K | $0.00 | $0.00 | $0.00 |
| Gross profit | $112.5M | $14.7M | $622.0K | $240.0K |
| Operating expenses | $368.6M | $358.9M | $362.9M | $351.5M |
| Operating income | -$256.0M | -$344.2M | -$362.3M | -$351.3M |
| Net income | -$351.4M | -$413.6M | -$583.2M | -$416.6M |
| EBITDA | -$223.6M | -$264.4M | -$478.7M | -$351.9M |
| Basic EPS | $-0.38 | $-0.59 | $-1.15 | $-1.04 |
| Diluted EPS | $-0.38 | $-0.62 | $-1.15 | $-1.04 |
| Balance sheet | ||||
| Cash & equivalents | $88.3M | $143.4M | $265.5M | $104.6M |
| Total assets | $501.9M | $382.9M | $504.5M | $362.4M |
| Total liabilities | $1.0B | $871.1M | $1.1B | $812.2M |
| Stockholders’ equity | -$499.6M | -$489.1M | -$587.0M | -$447.3M |
| Total debt | $878.1M | $504.2M | $726.7M | $723.8M |
| Net debt | $789.8M | $360.7M | $461.3M | $619.1M |
| Cash flow | ||||
| Operating cash flow | -$304.9M | -$391.2M | -$366.8M | -$337.5M |
| Capital expenditure | -$3.8M | -$6.9M | -$30.6M | -$78.2M |
| Free cash flow | -$308.8M | -$398.1M | -$397.3M | -$415.7M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | -$616.0K |